[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646153":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":83,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Pecs","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Left bundle branch block patients",null,"LBBB Cohort (qLV-guided Cardiac Resynchronization Therapy)\n\nPatients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and complete left bundle branch block (LBBB) according to contemporary guideline criteria. Cardiac resynchronization therapy is performed using a personalized implantation strategy guided by the qLV ratio, defined as the interval between QRS onset and local left ventricular activation divided by the intrinsic QRS duration. The left ventricular lead is positioned at the site with the longest achievable electrical delay to maximize resynchronization benefit. Patients receive either conventional biventricular CRT or LOT- CRT according to clinical decision-making and anatomical feasibility. The cohort is followed longitudinally to evaluate the relationship between qLV-guided lead placement, electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.",[13],"Device: Physiologic cardiac resynchronization using conduction system pacing and selective LV lead optimization.",{"label":15,"type":10,"description":16,"interventionNames":17},"Intraventricular conduction delay patients","IVCD Cohort (Conduction System Pacing-Guided Resynchronization Strategy)\n\nPatients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and intraventricular conduction delay (IVCD) without typical left bundle branch block morphology. The resynchronization strategy is guided by the degree of electrical correction achieved with conduction system pacing. During implantation, left bundle branch area pacing (LBBAP) is attempted and paced QRS duration is assessed. If conduction system pacing alone results in a paced QRS duration greater than 130 ms, a Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT) system is implanted by adding a left ventricular lead to further improve ventricular synchrony. The cohort is followed longitudinally to evaluate the association between electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Physiologic cardiac resynchronization using conduction system pacing and selective LV lead optimization.","Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.",[15,9],[25,26],"Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.","Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Peter Ezer MD PhD, assistant professor","CONTACT","+36305468840","ezerpeti@gmail.com",[34],{"facility":35,"status":10,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"Heart Institute , University of Pécs","Pécs","Baranya","7621","Hungary","HU",{"type":42,"coordinates":43},"Point",[44,45],18.22814,46.07617,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Peter Ezer","MD PhD Assistant professor of Cardiology",[52],{"name":53,"class":6},"Medical University of Pecs","100646153","restoration-of-synchronous-cardiac-function-due-to-physiologic-cardiac-pacing-modalities-with-clinical-endpoints-100646153",false,"NCT07684547","REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints","REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints RESYNC-PACE","RESYNC-PACE","Inclusion Criteria:\n\n* Age ≥18 years.\n* Symptomatic heart failure despite guideline-directed medical therapy.\n* Left ventricular ejection fraction (LVEF) ≤40%.\n* Indication for cardiac resynchronization therapy according to contemporary ESC guideline recommendations.\n* QRS duration ≥150 ms with either:\n\nLeft bundle branch block (LBBB), or Intraventricular conduction delay (IVCD).\n\n* Planned implantation of a CRT system\n* Ability to provide written informed consent\n* Expected survival greater than 24 months.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years and Age 100 \\\u003C years\n* Pregnancy or breastfeeding.\n* Inability or unwillingness to provide informed consent.\n* Life expectancy \\\u003C12 months due to non-cardiac comorbidities.\n* Active systemic infection or infection involving a cardiac implantable electronic device.\n* Reversible causes of heart failure expected to improve without CRT.\n* Participation in another interventional clinical trial that may affect study outcomes.\n* Inability to comply with follow-up requirements.\n* Missing essential baseline or follow-up data (retrospective cohort).\n* Any condition that, in the opinion of the investigators, would make participation inappropriate or interfere with study assessments.","ALL","18 Years","100 Years",{"count":66,"type":67},50,"ESTIMATED","24 Months","OBSERVATIONAL","The goal of this observational study is to evaluate the long-term clinical outcomes of physiologic cardiac resynchronization therapy (CRT) using conduction system pacing strategies compared with conventional biventricular CRT in patients with heart failure with reduced ejection fraction (HFrEF) and electrical dyssynchrony.\n\nThe main questions it aims to answer are:\n\n* Does physiologic CRT (including left bundle branch area pacing \\[LBBAP\\] and LBBAP-optimized CRT) reduce the combined risk of all-cause mortality and heart failure hospitalization compared with conventional biventricular CRT?\n* Does physiologic CRT improve cardiac function and reverse ventricular remodeling more effectively than conventional CRT?\n\nParticipants receiving physiologic CRT as part of routine clinical care will undergo standard follow-up evaluations, including electrocardiography, echocardiography, laboratory testing, and device interrogation. Clinical outcomes will be collected prospectively for 24 months and compared with a historical cohort of patients treated with conventional biventricular CRT.\n\nThe study will assess clinical outcomes, echocardiographic response, electrical resynchronization parameters, and device-related safety in a real-world heart failure population.",[72,73,74,75,76],"Heart Failure - NYHA II - IV","Left Bundle Branch Area Pacing","Left Bundle Branch Block","Intraventricular Conduction Delay","Resynchronization Therapy",[78,79,80,81,82],"carrdiac resynchornization therapy","Physiologic Pacing","Conduction System Pacing","Electrical Resynchronization","Physiologic CRT","NOT_YET_RECRUITING","2026-07-08",{"date":86,"type":87},"2026-07-10","ACTUAL",{"date":89,"type":67},"2026-06-29",{"date":91,"type":67},"2031-06-29",{"name":5,"class":6},1]